Health Care [ 4/12 ] | Biotechnology [ 24/73 ]
NASDAQ | Common Stock
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.
In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 1, 25 | -0.18 Increased by +86.86% | -0.31 Increased by +41.92% |
| Aug 7, 25 | -1.26 Increased by +8.70% | -0.86 Decreased by -46.51% |
| May 7, 25 | 2.75 Increased by +369.61% | -0.46 Increased by +694.98% |
| Feb 4, 25 | -1.39 Decreased by -12.10% | -0.72 Decreased by -92.15% |
| Nov 27, 24 | -1.37 Decreased by -34.31% | -0.92 Decreased by -48.59% |
| Aug 8, 24 | -1.38 Decreased by -43.75% | -0.55 Decreased by -150.91% |
| May 9, 24 | -1.02 Decreased by -326.67% | -0.16 Decreased by -537.50% |
| Feb 6, 24 | -1.24 Decreased by -217.95% | -0.82 Decreased by -51.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 256.47 M Increased by +987.25% | -23.75 M Increased by +86.07% | Decreased by -9.26% Increased by +98.72% |
| Jun 30, 25 | 27.77 M Increased by +N/A% | -175.24 M Decreased by -2.60% | Decreased by -631.11% Decreased by N/A% |
| Mar 31, 25 | 542.71 M Increased by +N/A% | 370.44 M Increased by +395.65% | Increased by +68.26% Decreased by N/A% |
| Dec 31, 24 | 2.50 M Decreased by -29.60% | -173.09 M Decreased by -30.27% | Decreased by -6.92 K% Decreased by -85.04% |
| Sep 30, 24 | 23.59 M Increased by +46.54% | -170.54 M Decreased by -55.49% | Decreased by -722.95% Decreased by -6.10% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -170.79 M Decreased by -65.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -125.30 M Decreased by -357.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 3.55 M Decreased by -94.32% | -132.86 M Decreased by -221.51% | Decreased by -3.74 K% Decreased by -5.56 K% |